TSHA
NASDAQ · Biotechnology
Taysha Gene Therapies Inc
$6.21
-0.73 (-10.52%)
Open$6.83
Previous Close$6.94
Day High$6.83
Day Low$6.06
52W High$7.30
52W Low$2.25
Volume—
Avg Volume3.09M
Market Cap1.84B
P/E Ratio—
EPS$-0.38
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+880.0% upside
Current
$6.21
$6.21
Target
$60.86
$60.86
$45.99
$60.86 avg
$68.15
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 8.96M | 5.69M | 242.81M |
| Net Income | -99,827,305 | -57,033,310 | 41.01M |
| Profit Margin | -1,115.3% | -1,059.5% | 16.9% |
| EBITDA | -100,149,423 | -60,396,084 | 60.77M |
| Free Cash Flow | — | — | 46.40M |
| Rev Growth | +57.5% | +57.5% | -6.9% |
| Debt/Equity | 0.20 | 0.20 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $243.14 | +3.51% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $352.82 | +0.40% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $123.84 | -1.05% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $480.18 | +1.05% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $620.14 | -0.53% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.17 | -0.30% | 64.3 | 37.13B |